Landscape → Infectious Disease

Bacterial Infections

98 clinical trials

23 active

98 total (since 2015)

Phase 1 Active

49 total

Phase 2 Active

22 total

Phase 3 Active

16 total

Phase 4 Active

17 total

Top Sponsors (Industry)

Sorted by active Active Done Failed

Pfizer 2 0 2

Qpex Biopharma, Inc. 1 8 0

CanSino Biologics Inc. 1 2 0

Paratek Pharmaceuticals Inc 1 2 0

Vasomune Therapeutics, Inc. 1 0 0

Grifols Therapeutics LLC 1 0 0

Bausch Health Americas, Inc. 1 0 0

Joincare Pharmaceutical Group Industry Co., Ltd 1 0 0

Saptalis Pharmaceuticals LLC 1 0 0

Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) 1 0 0

MB PHARMA s.r.o. 1 0 0

Merck 0 4 0

Evopoint Biosciences Inc. 0 4 0

Tetraphase Pharmaceuticals, Inc 0 4 0

Shionogi 0 3 0

NCT07017777 RECRUITING

A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)

CanSino Biologics Inc. n=600

NCT06592586 RECRUITING

A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women

Minervax ApS n=338

NCT05645107 RECRUITING

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Grifols Therapeutics LLC n=386

NCT06444802 NOT YET RECRUITING

Model-informed Precision Dosing for Linezolid

University of Hamburg-Eppendorf n=28

NCT03969901 COMPLETED

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

Merck Sharp & Dohme LLC n=115

NCT03925480 COMPLETED

Preventing Young Infant Infections Using Azithromycin in Labour (PreYIAL) Trial

Murdoch Childrens Research Institute n=2,110

NCT03896685 COMPLETED

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)

Médecins Sans Frontières, France n=323

NCT02814916 COMPLETED

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

AbbVie n=199

NCT04841369 COMPLETED

Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)

CanSino Biologics Inc. n=3,420

NCT03580044 TERMINATED

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

Pfizer n=15

NCT04847921 TERMINATED

Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition

University of Colorado, Denver n=11

NCT05689229 COMPLETED

Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial

Beni-Suef University n=128

NCT02378480 COMPLETED

Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

Paratek Pharmaceuticals Inc n=655

NCT02753387 COMPLETED

Effect of Oral Preparation on Bacterial Colonization of the Pharyngeal Mucosa in Surgery of Head and Neck Cancer

Rennes University Hospital n=80

NCT02877927 COMPLETED

Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI

Paratek Pharmaceuticals Inc n=735

NCT02452047 COMPLETED

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)

Merck Sharp & Dohme LLC n=50

NCT05123755 RECRUITING

Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

Vasomune Therapeutics, Inc.

NCT06462235 RECRUITING

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

Pfizer

NCT05639647 RECRUITING

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

Pfizer

NCT05632315 RECRUITING

PMT for MDRO Decolonization

University of Pennsylvania

NCT07146217 NOT YET RECRUITING

Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection

Saptalis Pharmaceuticals LLC

NCT06135350 RECRUITING

Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

NCT06319235 RECRUITING

Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®

MB PHARMA s.r.o.

NCT06086626 COMPLETED

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

Shionogi

NCT04335539 COMPLETED

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants

Shionogi

NCT04215991 COMPLETED

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants

Shionogi

NCT02269319 COMPLETED

MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

MicuRx

NCT02690181 COMPLETED

Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.

GlaxoSmithKline

NCT04126031 TERMINATED

Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.

Pfizer

NCT05269121 WITHDRAWN

Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections

Adaptive Phage Therapeutics, Inc.

NCT03964493 COMPLETED

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection

TenNor Therapeutics Limited

NCT03747497 COMPLETED

Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

MicuRx

NCT03978091 COMPLETED

A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02436876 COMPLETED

Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites

Microbion Corporation

NCT02426918 COMPLETED

Study of Debio 1450 for Bacterial Skin Infections

Debiopharm International SA

NCT04263792 RECRUITING

[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects

University of Pennsylvania

NCT07104162 RECRUITING

A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment

Qpex Biopharma, Inc.

NCT07207291 RECRUITING

Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers

Joincare Pharmaceutical Group Industry Co., Ltd

NCT02687906 ACTIVE NOT RECRUITING

Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections

Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)

NCT05217537 RECRUITING

Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

Paratek Pharmaceuticals Inc

NCT03424525 COMPLETED

11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects

University of Pennsylvania

NCT06079775 COMPLETED

P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants

Qpex Biopharma, Inc.

NCT06547554 COMPLETED

A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants

Qpex Biopharma, Inc.

NCT07070375 COMPLETED

Pharmacokinetics and Safety of HRS-8427 in Healthy Volunteers and in Patients With Impaired Renal Function

Jiangsu HengRui Medicine Co., Ltd.

NCT06157242 COMPLETED

PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment

Qpex Biopharma, Inc.

NCT05590728 COMPLETED

Safety of Intravenous Apramycin in Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05584683 COMPLETED

A Pharmacokinetic Study of LP-001 in Children With a Bacterial Infection

Kaizen Bioscience Co.

NCT05645757 COMPLETED

Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05684705 COMPLETED

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

BioVersys AG

NCT04874948 COMPLETED

Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment

Michael Hoelscher

NCT05942820 TERMINATED

The Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of BWC0977 in Healthy Adult Volunteers

Bugworks Research Inc.

NCT03230916 COMPLETED

A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)

Merck Sharp & Dohme LLC

NCT05614895 COMPLETED

A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections

Hoffmann-La Roche

NCT05684718 COMPLETED

To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100

BioVersys AG

NCT03910673 COMPLETED

Intravenous Fosfomycin Pharmacokinetics Study

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05088421 COMPLETED

A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers

Bugworks Research Inc.

NCT02527681 TERMINATED

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

Basilea Pharmaceutica

NCT04801043 COMPLETED

To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

Evopoint Biosciences Inc.

NCT04787562 COMPLETED

Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function

Evopoint Biosciences Inc.

NCT04482569 COMPLETED

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin

Evopoint Biosciences Inc.

NCT04802863 COMPLETED

Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects

Evopoint Biosciences Inc.

NCT04100772 COMPLETED

Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above

CanSino Biologics Inc.

NCT05226923 COMPLETED

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

Sumitovant Biopharma, Inc.

NCT03939429 COMPLETED

Phase 1 Study of Oral QPX2015 in Healthy Adult Subjects

Qpex Biopharma, Inc.

NCT04578873 COMPLETED

Phase 1 Oral QPX7831 SAD and MAD in Healthy Adults

Qpex Biopharma, Inc.

NCT04808414 COMPLETED

SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers

Qpex Biopharma, Inc.

NCT05072444 COMPLETED

Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult Subjects

Qpex Biopharma, Inc.

NCT04380207 COMPLETED

P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV

Qpex Biopharma, Inc.

NCT02688790 TERMINATED

Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection

AbbVie

NCT03450187 COMPLETED

A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study

Tetraphase Pharmaceuticals, Inc

NCT03024034 COMPLETED

A Phase 1 TP-271 Oral PK Single Ascending Dose Study

Tetraphase Pharmaceuticals, Inc

NCT03234738 COMPLETED

A Phase 1 Safety and PK Study of IV TP-271

Tetraphase Pharmaceuticals, Inc

NCT03696550 COMPLETED

A Safety and PK Study of IV Eravacycline

Tetraphase Pharmaceuticals, Inc

NCT02475876 COMPLETED

PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children

Michael Cohen-Wolkowiez

NCT03361163 COMPLETED

Controlled Human Infection for Vaccination Against Streptococcus Pyogenes

Andrew Steer

NCT02750761 COMPLETED

A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)

Merck Sharp & Dohme LLC

NCT03590600 COMPLETED

A Single Ascending Dose Study of BTZ043

Michael Hoelscher

NCT03332732 COMPLETED

VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers

Venatorx Pharmaceuticals, Inc.

NCT03182504 COMPLETED

A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants

Hoffmann-La Roche

NCT02955459 COMPLETED

VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers

Venatorx Pharmaceuticals, Inc.

NCT02268279 COMPLETED

Pharmacokinetics and Safety of Solithromycin in Adolescents and Children

Melinta Therapeutics, Inc.

NCT06709521 RECRUITING

Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05914467 ACTIVE NOT RECRUITING

TDM-optimized Teicoplanin Dosing Versus Standard of Care

Radboud University Medical Center

NCT07285785 NOT YET RECRUITING

Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

Bausch Health Americas, Inc.

NCT05922124 RECRUITING

Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii

Rambam Health Care Campus

NCT03671967 RECRUITING

PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

Rambam Health Care Campus

NCT07004049 RECRUITING

Optimising TREATment for Severe Gram-Negative Bacterial Infections

National University of Singapore

NCT05783661 RECRUITING

Trial Comparing Conventional Antibiotic Strategies Versus Regimens Guided by Epidemiological Surveillance in Infected Patients With Cirrhosis (SURVIC_STUDY)

Eva Bonfill

NCT02572791 COMPLETED

Staph Household Intervention for Eradication (SHINE)

Washington University School of Medicine

NCT07122596 COMPLETED

EFFICACY OF PROLONGED INFUSION MEROPENEM IN CRITICALLY ILL PAEDIATRIC INTENSIVE CARE PATIENTS

Pakistan Navy Station Shifa Hospital

NCT05355350 WITHDRAWN

PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections

Rambam Health Care Campus

NCT03220074 COMPLETED

Linezolid for Treatment of Nontuberculous Mycobacterial Diseases

Mahidol University

NCT04785924 WITHDRAWN

Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

Wake Forest University Health Sciences

NCT03982030 WITHDRAWN

Dalbavancin Outpatient Pilot

Wake Forest University Health Sciences

NCT05586438 COMPLETED

Pharmacokinetics of Colistin in Critically-ill Patients With AKI Who Receive SLED

Mahidol University

NCT03369951 COMPLETED

Minocycline Pharmacokinetics (ACUMIN)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03397914 COMPLETED

Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections

National Cancer Institute, Egypt

NCT03233438 COMPLETED

Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Allergan

Data: ClinicalTrials.gov